All News

The randomized, placebo-controlled RESCUE phase 3 trial assessed clofutriben among individuals with ACTH-dependent endogenous Cushing syndrome.

Recently announced trial results demonstrate the efficacy of the biologic in multiple disease indications.

At weeks 16 and 24, approximately 57% and 60% of patients with moderate to severe atopic dermatitis, respectively, achieved at least 75% improvement in Eczema Area and Severity Index score.

Compared with a short-acting β agonist (SABA) alone, inhaled corticosteroids (ICS) with formoteral and ICS with a SABA were associated with better asthma control.

It is more important than ever to have pharmacists and pharmacy professionals practicing at the top of their license to assist patients in pharmacy deserts.

Health system pharmacies can enhance operational and financial performance by leveraging key performance indicators, data-driven tools, and automation, ultimately supporting the broader health system’s adaptability and growth within an evolving health care landscape.

Pharmacists play a critical role in treating patients with breast cancer and can help address their social determinant of health challenges.

Two clinical trials with MRD monitoring may be practice changing: TRACERx and AEGEAN.

ASCO is prioritizing the expansion of pharmacist involvement in its organization by recognizing pharmacists' contributions to safety standards, quality improvement initiatives, and certification programs.

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

In children aged 12, 18, and 24 months, there was no association between maternal COVID-19 exposure and abnormal scores on a neurodevelopment screening.

Opioid stewardship coordinator Stephanie Abel, PharmD, BCPS, discusses initiatives such as increasing naloxone access, refining pain management protocols, and addressing stigma around opioid use disorder, highlighting the importance of clear goals and emotional intelligence for effective stewardship programs.

Martha Rumore, PharmD, Esq, discusses the legal and regulatory complexities surrounding tirzepatide compounding following FDA’s removal of the drug from the shortage list, which prompted a lawsuit and led to ongoing uncertainty for 503A and 503B facilities regarding enforcement discretion and future compounding restrictions.

Approximately 15% of patients with polycythemia vera will progress to myelofibrosis.

Low levels of vitamin D was linked with increased obstructive Apnea-Hypopnea Index scores.

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).

In the results, 31% of patients maintained undetectable measurable residual disease 4 years after treatment.

Gut microbiome research is no longer an obscure field in cancer care.

ASHP investigators determined the severity and impact of ongoing drug shortages, with approximately 99% of respondents reporting that they experienced a shortage.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Following lung cancer diagnosis, adjusting lifestyle habits can improve treatment responses.

Further efforts may be required to urge eligible members of the public to get screened for lung cancer.

The simultaneous doses of both vaccines compared with individual RZV and quadrivalent high-dose inactivated influenza vaccine (HD-IIV4, Fluzone; Sanofi) had similar overall safety findings.

Patients with hereditary angioedema who received sebetralstat earlier had faster complete resolution of their attacks.

A patient with BPDCN finds her champion.

Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.

Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

Although patients hope for reduced costs, Pharma’s reaction to the IRA remains to be seen.